Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC.

Am J Pathol. 2013 Jul;183(1):288-95. doi: 10.1016/j.ajpath.2013.03.011.

2.

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC.

Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.

3.

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.

Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, Holemon H, Gioeli D.

PLoS One. 2012;7(6):e38950. doi: 10.1371/journal.pone.0038950. Epub 2012 Jun 27.

4.

The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor.

Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y, Wei M, Chen J, Gao X, Xu C, Mao JH, Sun Y.

Urol Oncol. 2013 Oct;31(7):1117-23. doi: 10.1016/j.urolonc.2011.11.030. Epub 2012 Jan 20.

PMID:
22264502
5.

The oncogenic potential of a prostate cancer-derived androgen receptor mutant.

Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, DeVere White RW.

Prostate. 2007 May 1;67(6):591-602.

PMID:
17262801
6.

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

Tesei A, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W.

PLoS One. 2013 May 8;8(5):e62657. doi: 10.1371/journal.pone.0062657. Print 2013.

7.

The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. Epub 2005 Jun 30.

8.
9.

Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.

He HJ, Gu XF, Xu WH, Yang DJ, Wang XM, Su Y.

Acta Pharmacol Sin. 2013 Feb;34(2):282-8. doi: 10.1038/aps.2012.130. Epub 2012 Oct 1.

10.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

11.

TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.

Daniels G, Li Y, Gellert LL, Zhou A, Melamed J, Wu X, Zhang X, Zhang D, Meruelo D, Logan SK, Basch R, Lee P.

Endocr Relat Cancer. 2014 Jan 16;21(1):127-42. doi: 10.1530/ERC-13-0293. Print 2014 Feb.

12.

Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.

Thelen P, Peter T, Hünermund A, Kaulfuss S, Seidlová-Wuttke D, Wuttke W, Ringert RH, Seseke F.

BJU Int. 2007 Jul;100(1):199-203. Epub 2007 May 4.

13.

Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.

Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.

Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723.

PMID:
18196538
14.

RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC.

Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.

15.

Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.

Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, Chai CY, Huang CH, Chen IJ.

Prostate. 2009 May 1;69(6):610-23. doi: 10.1002/pros.20919.

PMID:
19143029
16.

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.

Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.

Carcinogenesis. 2008 Jun;29(6):1148-56. doi: 10.1093/carcin/bgn109. Epub 2008 May 16.

PMID:
18487223
17.

Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.

Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.

Clin Cancer Res. 2013 Oct 15;19(20):5613-25. doi: 10.1158/1078-0432.CCR-13-1151. Epub 2013 Aug 30.

18.

Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.

Yan J, Xie B, Capodice JL, Katz AE.

Prostate. 2012 Feb;72(3):244-52. doi: 10.1002/pros.21426. Epub 2011 Jun 8.

PMID:
21656835
19.

Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.

Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD, Sachdeva G.

Endocr Relat Cancer. 2014 May 8;21(3):473-86. doi: 10.1530/ERC-13-0514. Print 2014 Jun.

20.

Words of wisdom: Re: Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Culig Z.

Eur Urol. 2014 May;65(5):1013. doi: 10.1016/j.eururo.2013.12.040. No abstract available.

PMID:
24646498

Supplemental Content

Support Center